BioSpace News Archive

The data are being presented today in an oral presentation at the 2017 ASH Annual Meeting.

Bioverativ presented data demonstrating that BIVV009, its first-in-class monoclonal antibody currently in Phase 3 clinical development for the treatment of cold agglutinin disease (CAgD), was generally well tolerated, rapidly halted hemolysis, and improved anemia in six of six severely anemic primary CAgD patients in a Phase 1b clinical trial.

CRISPR gene-editing in hematopoietic stem cells demonstrates potential to treat β-thalassemia and sickle cell disease through upregulation of fetal hemoglobin.

The data includes up to two years of follow-up from the low-dose cohort and up to 18 months of follow-up from the second, higher-dose cohort.

Valerijs Maligins became Chairman of Olainfarm’s Board after the privatization of the company in 1997.

112 pediatric patients with a median follow-up of 18 months were reviewed in an oral presentation at the 59th Annual Meeting of the American Society of Hematology.

Sernova plans to initiate the new clinical trial under this US IND to investigate the Cell Pouch for tT1D in individuals with hypoglycemia unawareness.

Paclical will be sold through Hetero Group and is planned to be launched during the first half of 2018.

The initial dose escalation data suggest that the combination of zanubrutinib and tislelizumab had a manageable toxicity profile and anti-tumor activity in patients with B-cell malignancies.

Seattle Genetics today announced that the FDA has granted Breakthrough Therapy Designation to ADCETRIS in combination with chemotherapy for the frontline treatment of patients with advanced classical Hodgkin lymphoma.